CBD for beginners: 20 essential questions in France (2026)

CBD, or cannabidiol, is one of the main cannabinoids present in the hemp plant (Cannabis sativa L.). Unlike THC (tetrahydrocannabinol), CBD is non-intoxicating: it does not produce a euphoric psychotropic effect. MILDECA, the French government body, describes it as a substance "having no notable psychoactive effect".

Yes, since the Conseil d'État decision of 29 December 2022 (no. 444887). That decision annulled the interministerial order banning the sale of hemp flowers and leaves. The criterion now applied is: less than 0.30% THC in the finished product, derived from hemp varieties listed in the European or French catalogue. The Cour de cassation consolidated this line in a series of rulings on 14 January 2025.

0.30% maximum in the finished product. Take care: you will still hear about 0.2% (the former pre-2021 threshold) or "0.3% in the plant" — these formulations are incorrect. The benchmark applicable since 2021-2022 is 0.30% in the finished product, measured by chromatography in an accredited laboratory.

Yes. This is one of the most poorly understood risks. The Cour de cassation, in its ruling of 21 June 2023 (no. 22-85.530), held that "authorisation to market certain cannabis derivatives […] has no bearing on the offence of driving after using narcotics". In other words: the commercial lawfulness of the product does not exempt the driver. A saliva test positive for THC, even after a legal product, carries a penalty of 2 years' imprisonment and a €4,500 fine (Article L.235-1 of the Highway Code).

THC can be detected in saliva 6 to 8 hours after occasional use, up to 24 hours for regular use, and several days for chronic use. Do not drive after consuming full-spectrum or broad-spectrum CBD.

Users frequently report a feeling of relaxation, a moment of calm in an end-of-day routine, or muscle comfort after physical activity (for topical use). These descriptions are self-reported. No French authority has validated any health claim for CBD — not on stress, not on sleep, not on pain.

No. No CBD product sold in shops in France holds a marketing authorisation (AMM) as a medicine. The only CBD-based medicine authorised in France is Epidyolex®, prescribed in hospital settings for certain rare childhood epilepsies. Any seller claiming that CBD "cares for", "treats" or "cures" is exposed to prosecution for the illegal practice of pharmacy (Article L.4223-1 of the Public Health Code).

CBD interacts with the endocannabinoid system, a network of receptors (CB1, CB2) involved in regulating many physiological functions. CBD, unlike THC, does not bind directly to the CB1 receptors in the brain. It acts through indirect pathways that are still the subject of scientific study. The precise mechanisms have not all been elucidated, and EFSA considers that the data remain insufficient to conclude on specific effects.

This is the trickiest question. EFSA, in its opinion of 9 February 2026, set a provisionally safe daily dose of 0.0275 mg/kg of body weight per day, that is roughly 2 mg/day for a 70 kg adult. This provisional safe level is far below the dosages commonly recommended by brands (often 25 to 50 mg per serving). Pending further toxicological data, the prudent approach is to increase very gradually, starting with a fraction of a pipette.

• Flowers and resins (vaporising or infusion) — legal since December 2022.
• Sublingual oils — a segment being restructured following the Novel Food regulation.
• Cosmetics (creams, balms, topical oils) — the most stable regime, with CBD listed in the European CosIng database since 2021.
• E-liquids — subject to Directive TPD 2014/40/EU, bottles ≤ 10 ml.
• Foods and drinks — progressive withdrawal since 15 May 2026 by the DGAL of products not authorised under Novel Food.

Both refer to the same botanical species, Cannabis sativa L. The distinction is legal and chemical: industrial hemp contains less than 0.30% THC and is grown legally from varieties listed in the European catalogue. Marijuana refers to varieties with a high THC content (generally 15 to 25%), classified as narcotics.

CBD itself is not looked for by the saliva tests used by law enforcement, which target THC. But as explained above, a full-spectrum or broad-spectrum CBD product contains traces of THC that can make the test positive.

CBD is generally well tolerated at common doses, but ANSES proposed in June 2025 that it be classified as presumed toxic to human reproduction (CLP category 1B), on the basis of animal studies. Known adverse effects include: drowsiness, dry mouth, lowered blood pressure, digestive disturbances, and interactions with many medicines via cytochrome P450 (anticoagulants, antiepileptics and immunosuppressants in particular).

Since the ANSM order of 3 June 2024, the following are classified as narcotics in France: H4CBD, H2CBD, HHCPO, THCP, THCA, 10-OH-HHC. HHC and its derivatives HHC-O and HHC-P had already been classified since June 2023. Any shop or product containing these molecules is committing a criminal offence.

Not exactly. Since 15 May 2026, the DGAL has been strictly applying the European Novel Food regulation: CBD food products (gummies, bud-based infusions, ingestible capsules, drinks) are withdrawn from the market if they do not hold a European authorisation. Flowers (for inhaling or vaporising), oils for external use and cosmetics remain authorised.

ANSES and the medical community converge on the following contraindications:

• Pregnant or breastfeeding women
• Women of childbearing age wishing to conceive
• Under-25s (the group targeted by the EFSA provisional safe level)
• People on medical treatment (consult the prescribing doctor)
• People with liver conditions

Ask for the certificate of analysis (CoA). This document, issued by an independent laboratory, must state:

• The actual CBD concentration (often ± 10% compared with the label).
• The THC level, which must be ≤ 0.30% in the finished product.
• The absence of pesticides, heavy metals and residual solvents.
• The absence of banned cannabinoids (HHC, H4CBD, THCP).

The DGCCRF recorded a non-compliance rate of about 15% in 2024 across more than 1,200 inspections, relating mainly to claims and non-compliant labelling.

Yes. CBD is metabolised by cytochrome P450 enzymes, which also metabolise many medicines. Those concerned include: anticoagulants (warfarin), antiepileptics (clobazam, valproate), immunosuppressants, statins, and certain antidepressants and anxiolytics. Before any use alongside a treatment, ask your doctor or pharmacist for advice.

Medical cannabis is a treatment prescribed by a hospital doctor for specific indications (refractory neuropathic pain, drug-resistant epilepsies, MS spasticity, oncology, palliative care). It contains THC at active concentrations (up to 22%) and is subject to reinforced pharmacovigilance. The roll-out was notified to the European Commission in March 2025.

Wellbeing CBD is an everyday consumer product, sold without prescription and with no recognised therapeutic indication. The two are not interchangeable.

CBD is not a medicine. If a symptom persists, or if you have a question about a drug interaction, consult a healthcare professional.

• CBD is legal in France if the finished product contains less than 0.30% THC.
• It is not a medicine and no therapeutic claim is permitted.
• A legal CBD product can produce a saliva test positive for THC.
• EFSA recommends not exceeding about 2 mg/day for an adult.
• HHC, H4CBD, THCP and derivatives have been banned since June 2024.
• Not advised for pregnant or breastfeeding women, minors, or people on medication.
• Always insist on a certificate of analysis (CoA) before buying.

• Conseil d'État, interim order, 24 Jan. 2022, no. 460055 — primary
• ANSES — Press release of 19 June 2025 on the classification of CBD as reprotoxic (PDF) — primary
• ANSES — Opinion, Referral no. 2024-SA-0040 — primary